Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Qfitlia. Always confirm against the full prescribing information.
32 interactions
Albutrepenonacog alfa
The risk or severity of hypercoagulability can be increased when Albutrepenonacog alfa is combined with Fitusiran.
Level 1 evidence
Andexanet alfa
The risk or severity of hypercoagulability can be increased when Andexanet alfa is combined with Fitusiran.
Level 1 evidence
Anti-inhibitor coagulant complex
The risk or severity of hypercoagulability can be increased when Anti-inhibitor coagulant complex is combined with Fitusiran.
Level 1 evidence
Antihemophilic factor human
The risk or severity of hypercoagulability can be increased when Antihemophilic factor human is combined with Fitusiran.
Level 1 evidence
Antihemophilic factor, human recombinant
The risk or severity of hypercoagulability can be increased when Antihemophilic factor, human recombinant is combined with Fitusiran.
Level 1 evidence
Beroctocog alfa
The risk or severity of hypercoagulability can be increased when Beroctocog alfa is combined with Fitusiran.
Level 1 evidence
Calcium
The risk or severity of hypercoagulability can be increased when Calcium is combined with Fitusiran.
Level 1 evidence
Catridecacog
The risk or severity of hypercoagulability can be increased when Catridecacog is combined with Fitusiran.
Level 1 evidence
Coagulation Factor IX (Recombinant)
The risk or severity of hypercoagulability can be increased when Coagulation Factor IX (Recombinant) is combined with Fitusiran.
Level 1 evidence
Coagulation Factor IX Human
The risk or severity of hypercoagulability can be increased when Coagulation Factor IX Human is combined with Fitusiran.
Level 1 evidence
Coagulation factor VII human
The risk or severity of hypercoagulability can be increased when Coagulation factor VII human is combined with Fitusiran.
Level 1 evidence
Coagulation factor VIIa Recombinant Human
The risk or severity of hypercoagulability can be increased when Coagulation factor VIIa Recombinant Human is combined with Fitusiran.
Qfitlia (Fitusiran) has 32 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Qfitlia (Fitusiran) has 0 major, 0 moderate, and 32 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Qfitlia. Always confirm against the full prescribing information.